ADT1183-Drozitumab Biosimilar-(TNFRSF10B/CD262/TRAILR2)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1183 |
Product Name |
ADT1183-Drozitumab Biosimilar-(TNFRSF10B/CD262/TRAILR2)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names TNFRSF10B antibody, CD262 antibody, cd262 mouse, anti-mouse CD262 antibody, anti-CD262 antibody, anti CD262 antibody, recombinant CD262, anti-CD262 monoclonal antibody, CD262 antibodies, CD262 recombinant antibody, CD262 blocking antibody, TNFRSF10B recombinant antibody, TNFRSF10B blocking antibody |
|
Alias |
PRO95780, anti-DR5, rhuMAb DR5
|
Host |
CHO Cells |
Species |
Human |
Target |
TNFRSF10B/CD262/TRAILR2 |
Gene ID |
8795 |
Isotype |
IgG1 Lambda |
Size |
100ug, 1mg, 5mg |
Research Area |
Cancer |
CAS Number |
912628-39-8 |
Product Description |
Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response. |
Application |
ELISA, FC, IP, Functional assay, IF, Neut |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Mora-Molina R, et al. Int J Mol Sci, 2022 Aug 12. PMID 36012252
2. Qin J, et al. Expert Rev Respir Med, 2022 Jul. PMID 35822538
3. Sullivan GP, et al. Dev Cell, 2020 Mar 23. PMID 32109381
|